Spero Therapeutics (SPRO) Change in Account Payables (2016 - 2025)
Historic Change in Account Payables for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $615000.0.
- Spero Therapeutics' Change in Account Payables fell 8187.98% to $615000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 19414.48%. This contributed to the annual value of $5.9 million for FY2024, which is 67897.5% up from last year.
- Per Spero Therapeutics' latest filing, its Change in Account Payables stood at $615000.0 for Q3 2025, which was down 8187.98% from -$985000.0 recorded in Q2 2025.
- In the past 5 years, Spero Therapeutics' Change in Account Payables registered a high of $3.7 million during Q1 2022, and its lowest value of -$5.5 million during Q1 2025.
- Over the past 5 years, Spero Therapeutics' median Change in Account Payables value was $275000.0 (recorded in 2023), while the average stood at $12684.2.
- Its Change in Account Payables has fluctuated over the past 5 years, first soared by 506470.59% in 2024, then plummeted by 42825.83% in 2025.
- Spero Therapeutics' Change in Account Payables (Quarter) stood at -$2.1 million in 2021, then rose by 4.51% to -$2.0 million in 2022, then surged by 113.98% to $275000.0 in 2023, then skyrocketed by 342.18% to $1.2 million in 2024, then plummeted by 49.42% to $615000.0 in 2025.
- Its last three reported values are $615000.0 in Q3 2025, -$985000.0 for Q2 2025, and -$5.5 million during Q1 2025.